Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Easi-child Pilot study: Early Ivabradine in Pediatric Heart Failure
2025-520916-32-00Phase 2Authorised
- Sponsor
- Ospedale Pediatrico Bambino Gesù
- Start
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ivabradine in heart failure (HF), dilated cardiomyopathy (DCM) and Acute Heart Failure (AHF), sponsored by Ospedale Pediatrico Bambino Gesù. Primary endpoint: Primary clinical heart rate response at 14 days of stable ivabradine therapy. Planned start Mar 2025; status: authorised.
02
Drugs
ivabradine
03
Conditions
heart failure (HF)dilated cardiomyopathy (DCM)Acute Heart Failure (AHF)
Beyond the preview
Go deeper on 2025-520916-32-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-520916-32-00.